Old Web
English
Sign In
Acemap
>
authorDetail
>
Helen Moon
Helen Moon
Kaiser Permanente
Medicine
Internal medicine
Oncology
Metastatic renal cell cancer
Interleukin 2
7
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
2019
Mayer Fishman
Janice P. Dutcher
Joseph I. Clark
A. álva
Gerald P. Miletello
Brendan D. Curti
Neeraj Agarwal
Ralph J. Hauke
Kathleen M. Mahoney
Helen Moon
Jonathan S. Treisman
Scott S. Tykodi
Gregory A. Daniels
Michael A. Morse
M. Wong
Howard L. Kaufman
Nancy C. Gregory
David F. McDermott
Show All
Source
Cite
Save
Citations (6)
Immune-related adverse events (IrAE) of elderly patients (pts) receiving PD-1 or PDL-1 inhibitors (PDIs) in a community-oncology setting: The experience at Kaiser Permanente California.
2018
Journal of Clinical Oncology
Thach-Giao Truong
Christopher Yamamoto
Timothy Chiu
Fang Niu
Michele M. Spence
Jim Chan
Robert Michael Cooper
Helen Moon
Rita L. Hui
Show All
Source
Cite
Save
Citations (2)
Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.
2018
Journal of Clinical Oncology
Mayer Fishman
Joseph I. Clark
Ajjai Alva
Brendan D. Curti
Neeraj Agarwal
Ralph J. Hauke
Kathleen M. Mahoney
Helen Moon
Jonathan Treisman
Scott S. Tykodi
Gregory A. Daniels
Michael A. Morse
Michael K. K. Wong
Howard L. Kaufman
Nancy C. Gregory
Janice P. Dutcher
Show All
Source
Cite
Save
Citations (0)
1